IKT — Inhibikase Therapeutics Share Price
0.000.00%
Last trade - 00:00- $11.08m
- -$2.18m
- $0.26m
- 15
- 17
- 54
- 19
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.01 | ||
| Price to Tang. Book | 1.01 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 42.52 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -181.51% | ||
| Return on Equity | -118.88% | ||
| Operating Margin | -7712.01% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1.12 | 0.7 | 3.1 | 0.12 | 0.26 | n/a | n/a | -42.21% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for Parkinson’s disease and related disorders. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its lead program risvodetinib (also known as IkT-148009), an Abelson Tyrosine Kinase (c-Abl) inhibitor, targets the treatment of Parkinson’s disease inside and outside the brain as well as other diseases that arise from Ableson Tyrosine Kinases. Its multi-therapeutic pipeline is pursuing Parkinson’s-related disorders of the brain and GI tract, orphan indications related to Parkinson’s disease such as Multiple System Atrophy, and drug delivery technologies for kinase inhibitors such as IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate. The Company’s RAMP medicinal chemistry program has identified a number of follow-on compounds to IkT-148009 to be potentially applied to other cognitive and motor function diseases of the brain.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 3rd, 2010
- Public Since
- December 23rd, 2020
- No. of Shareholders
- 14
- No. of Employees
- 8
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 6,476,844
- Address
- 3350 Riverwood Parkway Se, Suite 1900, ATLANTA, 30339
- Web
- https://www.inhibikase.com/
- Phone
- +1 6783923419
- Contact
- Alex Lobo
- Auditors
- CohnReznick LLP
Upcoming Events for IKT
Inhibikase Therapeutics Inc Annual Shareholders Meeting
Inhibikase Therapeutics Inc Annual Shareholders Meeting
Q2 2024 Inhibikase Therapeutics Inc Earnings Release
Similar to IKT
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Inhibikase Therapeutics share price?
As of Today at 19:11 UTC, shares in Inhibikase Therapeutics are trading at $1.71. This share price information is delayed by 15 minutes.
How has the Inhibikase Therapeutics share price performed this year?
Shares in Inhibikase Therapeutics last closed at $1.71 and the price had moved by -46.02% over the past 365 days. In terms of relative price strength the Inhibikase Therapeutics share price has underperformed the S&P500 Index by -55.87% over the past year.
What are the analyst and broker recommendations for Inhibikase Therapeutics?
The overall consensus recommendation for Inhibikase Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Inhibikase Therapeutics dividend yield?
Inhibikase Therapeutics does not currently pay a dividend.
Does Inhibikase Therapeutics pay a dividend?
Inhibikase Therapeutics does not currently pay a dividend.
When does Inhibikase Therapeutics next pay dividends?
Inhibikase Therapeutics does not currently pay a dividend.
How do I buy Inhibikase Therapeutics shares?
To buy shares in Inhibikase Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Inhibikase Therapeutics?
As of the previous close price of $1.71, shares in Inhibikase Therapeutics had a market capitalisation of $11.08m.
Where are Inhibikase Therapeutics shares listed?
Here are the trading details for Inhibikase Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: IKT
What kind of share is Inhibikase Therapeutics?
Based on an overall assessment of its quality, value and momentum Inhibikase Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Inhibikase Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Inhibikase Therapeutics is $17.50. That is 923.39% above the last closing price of $1.71.
Analysts covering Inhibikase Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$1.77 for the next financial year.
What is the trend in the Inhibikase Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Inhibikase Therapeutics. Over the past six months, its share price has outperformed the S&P500 Index by +67.85%.
As of the last closing price of $1.71, shares in Inhibikase Therapeutics were trading -5.18% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Inhibikase Therapeutics PE Ratio?
The Inhibikase Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.71.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Inhibikase Therapeutics?
We do not have data on Inhibikase Therapeutics' directors